June 9, 2026 RSS (“Nuvalent”) (NASDAQ: NUVL) a Boston-based clinical-stage biopharmaceutical company focused on creating precisely targeted oncology therapies, for … Read more: GSK enters agreement to acquire Nuvalent, Inc.